Inactive

The U. S. Food & Drug Administration, (FDA) Office of Acquisition and Grants Services (OAGS) has a requirement to procure a CFSAN-2023-114792-High Content Screening System, under solicitation FDA-RFQ-... The U. S. Food & Drug Administration, (FDA) Office of Acquisition and Grants Services (OAGS) has a requirement to procure a CFSAN-2023-114792-High Content Screening System, under solicitation FDA-RFQ-75F40123Q00015-CFSAN-2023-114792. The purpose of Amendment 001 is to, per attachment: Amendment 0001: i.Delete the all verbiage in the RFQ relating to PMA ii. Correct the RFQ due Date, which is 11/30/2022. Every other terms and conditions remain the same.